StockUS listing USZVSANASDAQHealthcareCapital Destroyer

ZyVersa Therapeutics Inc.(ZVSA) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk58Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 801496
Reward Ratingⓘ40 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ58 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ZVSA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is ZyVersa Therapeutics Inc.?

, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.

AI Brief Pro

The brief on ZyVersa Therapeutics Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is ZyVersa Therapeutics Inc.?

, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 801.50K.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap801.50K
Beta0.867
Insider Activity
12M windowNo data
No insider activity data available for this ticker.